

Iris Grossman, Ph.D.
Chief Scientific Officer, Camp4 Therapeutics

Dr. Iris Grossman has dedicated her research career, in both industry and academia, to the advancement of the field of personalized medicine and to embedding translational medicine (biological and digital) into all stages of the discovery, development and life-cycle management of pharmaceutical assets. Solving the riddle of abnormal disease regulation as means to optimize the benefit/risk profile of therapeutics in R&D, Dr. Grossman leads research at Camp4 Therapeutics, as Chief Scientific Officer. Championing Biomarker and digital health innovation in R&D and real-world application, Dr. Grossman is also co-founder and CEO of the consultancy firm IsraGene. In her most recent corporate position she was head of the Early Stage Clinical Development unit and Teva Pharmaceuticals, where she was charged with defining and implementing the global Personalized Medicine and Analytics strategy for Teva R&D (2013-2018).